Strategic partnerships Leverage ongoing licensing activity with Servier and recent ASCO exposure to position BD Therapeutics as a partner of choice for co-development or commercialization in RAF- and RAS-mutant solid tumors, expanding global reach and pipeline validation.

Executive engagement Capitalizing on high-visibility leadership involvement at investor conferences and executive leadership changes can open doors for strategic outreach to big pharma and precision oncology funds seeking collaboration on MasterKey therapies.

Clinical momentum Target clinicians and institutions participating in ASCO and other major oncology forums where BD Therapeutics presents data on BDTX-1535 and silevertinib to identify early-adopter centers for collaboration, access programs, or investigator-initiated studies.

Brain penetration niche Position silevertinib’s brain-penetrant EGFR inhibition as a differentiator for NSCLC and GBM programs to attract translational research partners, CMOs, and contract research organizations focused on CNS-oncology trials and biomarker-enabled trials.

Financial and valuation signal Use the company’s current revenue range and substantial funding as a validation point to pursue co-investment opportunities, licensing, and milestone-based deals with mid-to-large biotechs seeking risk-mared oncology assets with scalable addressable patient populations.